## SUPPLEMENTARY APPENDIX

Activation-induced markers (AIM) T cell assay	1
List of Reagents	2
Figure S1	3
Table S1. Demographic data of the study's         participants	7
Table S2. Antibodies and fluorochromes used in the activation induced marker         (AIM) assay	8
Table S3. Statistical differences on IgG levels against wild-type SARS-CoV-2 andSARS-CoV-2 variants of concern (VOCs)	9

## Activation-induced markers (AIM) T cell assay - full protocol

PBMCs were thawed at 37°C and diluted in RPMI 1640 media (Thermo Scientific, MA, USA) supplemented with 5% human serum (Sigma-Aldrich, Darmstadt, Germany), 2 mM Lglutamine (Gibco, MA, USA), 1 mM penicillin/streptomycin (Gibco, MA, USA), 10 mM HEPES solution (Gibco, MA, USA), 1mM sodium pyruvate (Gibco, MA, USA) and 55 mM  $\beta$ -mercaptoethanol (Gibco, MA, USA) (hereafter referred as HR5). Cells were centrifuged at 1500 rpm for 10 min, resuspended in HR5 containing 50 U/mL benzonase (Merck, Darmstadt, Germany) and incubated at 37°C and 5% CO<sub>2</sub> to remove DNA/RNA aggregates. After incubation, cells were counted, centrifuged at 1500 rpm for 10 min and seeded at a density of 1,5x10<sup>6</sup> cells per well, in U-bottom 96-well plates.

Cells were incubated with 0,5  $\mu$ g/mL anti-CD40 antibody (Miltenyi Biotec, NRW, Germany) for 15 min at 37°C and 5% CO<sub>2</sub> and then stimulated for 24h at 37°C and 5% CO<sub>2</sub> in the presence of specific MPs (1  $\mu$ g/mL), phytohemagglutinin (PHA, Sigma-Aldrich, Darmstadt, Germany) (10  $\mu$ L/mL) as a positive control or dimethyl sulfoxide (DMSO, Sigma-Aldrich, Darmstadt, Germany) (0,1 %) as a negative control, all diluted in HR5. MPs were developed and kindly donated by Dr. Alessandro Sette's laboratory (Center for Infectious Disease and Vaccine Research; La Jolla Institute for Immunology, USA) (Grifoni et al., 2020) and comprehend SARS-CoV-2-specific epitopes specified as CD4-R (remaining non-Spike protein), CD4-S (Spike protein) and CD8-A and CD8-B (viral epitopes compatible with HLA-A and HLA-B, respectively).

After a 24-hours MPs incubation, plates were centrifuged at 1800 rpm for 2 min and the supernatant was collected in a new plate and kept at -80°C freezer for further analysis. Cell pellets were resuspended, transferred to V-bottom 96-well plates and washed with MACS buffer (5 mg/mL bovine serum albumin (BSA, Sigma-Aldrich, Darmstadt, Germany) and 2 mM ethylenediamine tetraacetic acid (EDTA, Sigma-Aldrich, Darmstadt, Germany) diluted in phosphate-buffered saline 1X (PBS, LGC Biotecnologia, SP, Brazil)) twice, then stained with a specific antibodies mix containing characterization and activation markers (Supplementary Appendix) for 20 min, at 4°C in the dark (Moderbacher et al., 2020). After staining, cells were washed twice at the same conditions, fixed with paraformaldehyde (PFA, Sigma-Aldrich, Darmstadt, Germany), diluted 1:10 in PBS 1X, for 10 min at room temperature in the dark, centrifuged at 2000 rpm for 5 min, resuspended in PBS 1X and acquired at the BD LSRFortessa<sup>TM</sup> X-20 Cell Analyzer (BD Biosciences, CA, USA).

## List of Reagents

- 1. RPMI 1640 media (Thermo Scientific, MA, USA)
- 2. 5% human serum (Sigma-Aldrich, Darmstadt, Germany)
- 3. 2 mM L-glutamine (Gibco, MA, USA)
- 4. 1 mM penicillin/streptomycin (Gibco, MA, USA)
- 5. 10 mM HEPES solution (Gibco, MA, USA)
- 6. 1mM sodium pyruvate (Gibco, MA, USA)
- 7. 55 mM β-mercaptoethanol (Gibco, MA, USA)
- 8. 50 U/mL benzonase (Merck, Darmstadt, Germany)
- Specific SARS-CoV-2 megapools (Center for Infectious Disease and Vaccine Research; La Jolla Institute for Immunology)
- 10. anti-CD40 antibody (Miltenyi Biotec, NRW, Germany)
- 11. Phytohemagglutinin (PHA, Sigma-Aldrich, Darmstadt, Germany)
- 12. Dimethyl sulfoxide) (DMSO, Sigma-Aldrich, Darmstadt, Germany)
- 13. U-bottom 96-well culture plates (TPP, Trasadingen, Switzerland)
- 14. MACS buffer:
  - -5 mg/mL bovine serum albumin (BSA, Sigma-Aldrich, Darmstadt, Germany)
  - -2 mM ethylenediamine tetraacetic acid (EDTA, Sigma-Aldrich, Darmstadt, Germany)
     phosphate-buffered saline 1X (PBS, LGC Biotecnologia, SP, Brazil)
- 15. Paraformaldehyde (PFA, Sigma-Aldrich, Darmstadt, Germany), diluted 1:10 in PBS1X
- 16. V-bottom 96-well plates (NUNC, Thermo Scientific, MA, USA)
- V-PLEX SARS-CoV-2 Panel 7 IgG kit, catalogue number K15437U-4 (MesoScale Discovery, MD, USA)





A







3





Е

D

4







## Figure S1. Specific wt and VOCs SARS-CoV-2 strains IgG titers through one-year followup.

Graphs show anti-SARS-CoV-2 IgG levels in AU/mL from vaccinees throughout one year, and placebos and infected patients as controls. Symbol colours represent age-groups (black: 18-59, grey:  $\geq 60$ ). Symbol shapes represent different volunteer sub-groups (unfilled circle: placebos (n=8), filled circle: vaccinees (n=53), filled triangles: SARS-CoV-2 infected hospitalized 19 days of symptoms onset (median, 17-22 days IQR) (n=6) or non-hospitalized individuals, 46 days of symptoms onset (median, 34-65 days IQR) (n=6)). Od: vaccinee baseline, day of first vaccine dose. 14d: two-weeks after the first dose, day of the second vaccine dose. Mann-Whitney test was performed to compare both age groups in each visit, and asterisks indicate a statistically significant difference according to the p-value: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001. IgG levels were measured for (A) wild-type Spike protein; (B) wild-type RBD protein; (C) wild-type nucleocapsid protein; (D) Alpha Spike and RBD proteins; (E) Beta Spike and RBD proteins and (F) Gamma Spike and RBD proteins.

Groups Age*		Sex	Days between vaccine doses*	Days of symptoms onset*	COVID-19 Diagnosis	
Placebo (n=8)	54 (36-64)	62.5% F 37.5% M	-	-	-	
Vaccinees						
18-59 (n=29)	36 (31-42)	55.2% F 44.8% M	15 (14-18)	-		
≥60 (n=24)	67 (63-70)	33.3% F 66.7% M	16 (14-21)	-	-	
COVID-19 infected indiv	riduals					
Hospitalized (n=8)	53 (43-62)	12.5% F 87.5% M	-	19 (17-22)	75% PCR 25% Sorology	
Non-Hospitalized (n=9)	40 (33-44)	55.6% F 44.4% M	-	46 (34-65)	100% PCR	

Fluorochrome	AIM T CD4 <sup>+</sup> cells	AIM T CD8 <sup>+</sup> cells
BB515	CD3 (UCHT1)	CD3 (UCHT1)
APC-H7	CD4 (RPA-T4)	CD4 (RPA-T4)
PerCP CY5,5	CD8 (SK1)	CD8 (SK1)
BV786	PD1 (EH12.1)	-
APC	CD45RA (HI100)	CD45RA (HI100)
PE-CY7	CD25 (M-A251)	-
BV711	CXCR3 (1C6)	CXCR3(1C6)
BV421	CCR7 (G043H7)	CCR7 (G043H7)
Alexa Fluor 700	CD40/CD154 (24-31)	-
APC-R700	-	CD38 (HIT2)
BV510	CD137 (4B4-1)	CD137 (4B4-1)
BV605	CXCR5 (RF8B2)	-
PE	OX40 (Ber-ACT35)*	CD69 (FN50)
PE-CF594	Live-Dead**	Live-Dead**

**Table S2.** Antibodies and fluorochromes used in the activation induced marker (AIM) assay.

\*All antibodies were acquired from BD Biosciences, excepting from anti-OX40 (Biolegend). Clones were described in parenthesis. \*\*Cell viability marker, Live/Dead, CF-594, Life Technologies.

**Table S3.** Statistical differences on IgG levels (AU/ml) against SARS-CoV-2 wt and variants of concern (VOCs), Alpha, Beta and Gamma. First line of each protein target represents statistical differences between each age group (18-59 or  $\geq 60$ ) with respective baseline (0d) measures, and the second line represents statistical differences between both age groups (18-59 and  $\geq 60$ ).

Γ		0d		0d		14d		28d		42d		90d		180d		270d		365d	
		18-59	≥60	18-59	≥60	18-59	≥60	18-59	≥60	18-59	≥60	18-59	≥60	18-59	≥60	18-59	≥60		
ľ	N	-	-	>0,9999	>0,9999	< 0,0001	0,0756	<0,0001	0,0412	< 0,0001	0,0088	0,0159	0,0383	0,1902	0,8948	0,1004	>0,9999		
N		0,1675		0,0101		0,0003		<0,0001		0,0002		0,0562		0,1061		0,1984			
ſ	ut Spike	-	-	0,0004	0,2999	< 0,0001	<0,0001	<0,0001	< 0,0001	< 0,0001	<0,0001	< 0,0001	< 0,0001	0,0090	0,0012	0,0010	0,1182		
wi Spi	wi spike	0,5979 0,0002		0,0047 0,0157		0,4208		0,5239		0,5177		0,2404							
ſ		-	-	0,0015	0,3331	< 0,0001	<0,0001	<0,0001	< 0,0001	< 0,0001	<0,0001	< 0,0001	< 0,0001	0,0043	0,0070	0,0008	0,1448		
		0,11	02	0,0	007	0,0	095	0,0	211	0,5	463	>0,9	9999	0,1	816	0,4	980		
		-	-	0,0002	0,2779	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	0,0068	0,0074	0,0008	0,1919		
	u spike	0,70	32	32 0,0004		0,0077 0,0211		0,4533 0,3155		0,1598		0,1455							
		-	-	0,0018	0,3720	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	0,0022	0,0037	0,0008	0,1343		
		0,0188		0,0002		0,0047		0,0188		0,3600		0,8455		0,1705		0,3998			
	0 Spiko	-	-	0,0003	0,1816	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	0,0198	0,0043	0,0019	0,2120		
	h obive	0,73	96	0,0	003	0,0	067	0,0	072	0,2	964	0,1	615	0,1	816	0,1	164		
		-	-	0,0165	0,5523	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	0,0253	0,0038	0,0009	0,3004		
P KBD	PROD	0,0880 0,0023		0,0	0,0037 0,0051		0,3897 0,6306		306	0,2604		0,3698							
	v Sniko	-	-	0,0002	0,1953	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	0,0083	0,0003	0,0011	0,0854		
Ŷ	y Opine	0,3795		0,0002		0,0150		0,0298		0,4315		0,5585		0,7857		0,1036			
	VPBD	-	-	0,0025	0,3257	< 0,0001	<0,0001	<0,0001	< 0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0205	0,0033	0,0005	0,1286		
Y I	Y	0.01	31	0.0	002	0.0	034	0.0	044	0.2	558	0.9	689	02	171	0.4	164		

Colours represent statistical difference according to p-value, being grey: no significant, light yellow: \* p<0.05, light orange: \*\* p<0.01, light red: \*\*\* p<0.001 and red: \*\*\*\* p<0.0001.